Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Non-Current Assets (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Other Non-Current Assets data on record, last reported at $1.3 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 35.29% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, down 35.29%, while the annual FY2025 figure was $1.3 million, 35.29% down from the prior year.
  • Other Non-Current Assets reached $1.3 million in Q4 2025 per TGTX's latest filing, up from $1.3 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $2.3 million in Q4 2023 and bottomed at $1.3 million in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $1.4 million, with a median of $1.3 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 81.38% in 2023, then tumbled 35.29% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.3 million in 2021, then rose by 0.71% to $1.3 million in 2022, then soared by 81.38% to $2.3 million in 2023, then fell by 10.18% to $2.1 million in 2024, then tumbled by 35.29% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $1.3 million in Q4 2025, $1.3 million in Q3 2025, and $1.3 million in Q2 2025.